Banner Title
Blood Health Institute
Introduction
Currently, in the field of malignant hematologic diseases, various novel anticancer drugs, targeted therapies and cell therapy agents have either been developed or are on the verge of being commercialized, while pharmaceutical companies and biotech venture firms at home and abroad continue to research innovative new pharmaceuticals. Accordingly, the Blood Health Institute of Ewha Womans University Blood Cancer Hospital actively participates in these cutting-edge studies, and also focuses on providing patients with greater opportunities for treatment, discovering novel drug candidates, and establishing a new paradigm for the treatment of blood cancers. Professor Lee Kyu-hyung, the director of the institute, is a world-renowned scholar recognized for his research on haploidentical transplantation in acute leukemia. Recently, he has been conducting research aimed at integrating NK cell therapy into leukemia treatment, and he is now awaiting government approval following the development of a novel drug. Additionally, Professor Lee Seok has devoted several decades to the study of acute lymphoblastic leukemia, publishing more than five papers each year in internationally esteemed scholarly journals, while playing a key role in clinical research on the development of new drugs. Moreover, the professors affiliated with the institute are conducting clinical trials of novel therapeutics targeting lymphoma and multiple myeloma, and they are also actively involved in a number of cell therapy development projects under the “Inter-ministerial Regenerative Medicine Support Project.” The professors are also continuing with research aimed at finding fundamental solutions for blood cancer treatment, such as identifying novel pharmaceutical candidates and developing animal models for hematologic disorders, and relentlessly striving to achieve world-class research capabilities in the field of hematologic oncology. As such, the Blood Health Institute of Ewha Womans University Blood Cancer Hospital is committed to establishing an innovative platform that links research with clinical trials, and to doing its utmost to provide patients with more effective treatment options and, consequently, greater hope.